Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;26(1):40-5.
doi: 10.3802/jgo.2015.26.1.40. Epub 2014 Oct 13.

DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers

Masafumi Kato  1 , Masashi Takano  2 , Morikazu Miyamoto  1 , Naoki Sasaki  1 , Tomoko Goto  1 , Hitoshi Tsuda  3 , Kenichi Furuya  1
Affiliations

DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers

Masafumi Kato et al. J Gynecol Oncol. 2015 Jan.

Abstract

Objective: Recent investigations have revealed DNA mismatch repair (MMR) gene mutations are closely related with carcinogenesis of endometrial cancer; however the impact of MMR protein expression on prognosis is not determined. Correlations between MMR-related protein expression and clinicopathological factors of endometrial cancers are analyzed in the present study.

Methods: A total of 191 endometrial cancer tissues treated between 1990 and 2007 in our hospital were enrolled. Immunoreactions for MSH2, MLH1, MSH6, and PMS2 on tissue microarray specimens and clinicopathological features were analyzed retrospectively.

Results: Seventy-six cases (40%) had at least one immunohistochemical alteration in MMR proteins (MMR-deficient group). There were statistically significant differences of histology, International Federation of Gynecology and Obstetrics (FIGO) stage, and histological grade between MMR-deficient group and the other cases (MMR-retained group). Response rate of first-line chemotherapy in evaluable cases was slightly higher in MMR-deficient cases (67% vs. 44%, p=0.34). MMR-deficient cases had significantly better progression-free and overall survival (OS) compared with MMR-retained cases. Multivariate analysis revealed MMR status was an independent prognostic factor for OS in endometrial cancers.

Conclusion: MMR-related proteins expression was identified as an independent prognostic factor for OS, suggesting that MMR was a key biomarker for further investigations of endometrial cancers.

Keywords: Biological Markers; Carcinogenesis; DNA Mismatch Repair; Endometrial Neoplasms; Multivariate Analysis; Retrospective Studies.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival curves of all cases according to mismatch repair (MMR) status. (A) Progression-free survival (PFS) curve of MMR-retained cases (dotted line) and MMR-deficient cases (solid line). Five-year PFS was 92% in MMR-deficient patients, and 78% in MMR-retained patients (p=0.013). (B) Overall survival (OS) curves of MMR-retained cases (dotted line) and MMR-deficient cases (solid line). Five-year OS was 94% in MMR-deficient patients, and 78% in MMR-retained patients (p=0.009).
See this image and copyright information in PMC

References

    1. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2013;43:328–336. - PubMed
    1. Hirai Y, Banno K, Suzuki M, Ichikawa Y, Udagawa Y, Sugano K, et al. Molecular epidemiological and mutational analysis of DNA mismatch repair (MMR) genes in endometrial cancer patients with HNPCC-associated familial predisposition to cancer. Cancer Sci. 2008;99:1715–1719. - PMC - PubMed
    1. OECDiLibrary. Health at a glance [Internet] Paris: OECD; 2013. [cited 2014 Sep 9]. Available from: http://dx.doi.org/10.1787/health_glance-2013-en. - DOI
    1. Japanese Gynecologic Oncology Committee. Annual report of endometrial carcinoma patients in 2006. Acta Obstet Gynaecol Jpn. 2008;60:1034–1040.
    1. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–284. - PMC - PubMed

MeSH terms